10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CD7 (aa132-146) Antibody (internal region)

Peptide-affinity purified goat antibody
Catalog # AF3645a

Specification

CD7 (aa132-146) Antibody (internal region) - Product Information

Application	**WB**
Primary Accession	P09564
Other Accession	NP_006128.1, 924
Reactivity	**Human**
Host	**Goat**
Clonality	**Polyclonal**
Concentration	**0.5 mg/ml**
Isotype	**IgG**
Calculated MW	**25409**

CD7 (aa132-146) Antibody (internal region) - Additional Information

Gene ID 924

Other Names
T-cell antigen CD7, GP40, T-cell leukemia antigen, T-cell surface antigen Leu-9, TP41, CD7, CD7

Format
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
CD7 (aa132-146) Antibody (internal region) is for research use only and not for use in diagnostic or therapeutic procedures.

CD7 (aa132-146) Antibody (internal region) - Protein Information

Name CD7

Function
Not yet known.

Cellular Location
Membrane; Single-pass type I membrane protein.

CD7 (aa132-146) Antibody (internal region) - Protocols

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

CD7 (aa132-146) Antibody (internal region) - Images

AF3645a (0.5 µg/ml) staining of Human Thymus lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

CD7 (aa132-146) Antibody (internal region) - Background

The immunizing peptide corresponds to a part of the extracellular domain.

CD7 (aa132-146) Antibody (internal region) - References

Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia. Rogers SL, Zhao Y, Jiang X, Eaves CJ, Mager DL, Rouhi A. Mol Cancer. 2010 Feb 22;9:41. PMID: 20175919